Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naive HCV-infected Patients Treated With Pegylated Interferons.

Trial Profile

Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naive HCV-infected Patients Treated With Pegylated Interferons.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PROPHESYS-1
  • Sponsors Roche
  • Most Recent Events

    • 09 May 2016 Time frame of the primary end point changed from weeks 4 and 12, and 24 weeks after EOT to At 24 weeks after EOT.
    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Nov 2011 Planned end date changed from 1 Nov 2010 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top